Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.44 |
| ▸ | QPCT | Q16769 | 5/20 | 0.44 |
| ▸ | PRKCA | P17252 | 4/20 | 0.43 |
| ▸ | MAP2 | P11137 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | STK10 | O94804 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.41 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | TLK1 | Q9UKI8 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679888 | 0.93 | GSK3B (0.44) | GSK3BQPCTPRKCAGSK3ASTK10 | |
| SCHEMBL4682941 | 0.92 | GSK3B (0.43) | GSK3BQPCTPRKCAGSK3ASTK10 | |
| SCHEMBL2955240 | 0.77 | GSK3B (0.57) | GSK3BQPCTPRKCA | |
| SCHEMBL1127716 | 0.76 | GSK3B (0.64) | GSK3BQPCTPRKCA | |
| SCHEMBL14499020 | 0.75 | GSK3B (0.38) | GSK3BQPCTMAP2GSK3ASTK10 | |
| SCHEMBL5827727 | 0.66 | WEE1 (0.57) | — | |
| SCHEMBL1127953 | 0.66 | GSK3B (0.68) | GSK3BPRKCA | |
| SCHEMBL8163218 | 0.66 | GSK3B (0.81) | GSK3BPRKCAGSK3A | |
| SCHEMBL5754128 | 0.64 | PRKCA (0.85) | GSK3BPRKCA | |
| SCHEMBL14488857 | 0.64 | KCNH2 (0.44) | ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513520-B1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| EP-1513520-A2 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040054180-A1 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2004-03-18 | — | — | US | disclosed |
| WO-2003103663-A2 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054180-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | GSK3B 880/4885QPCT 2577/4885PRKCA 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.